西妥昔单抗和伊立替康联合腹腔镜手术治疗晚期转移性结直肠癌的疗效研究

目的 观察术前西妥昔单抗和伊立替康（FOLFIRI）方案化疗联合腹腔镜手术治疗晚期转移性结直肠癌的临床效果.方法 选取2011年6月～2013年6月期间在本院接受治疗的晚期转移性结直肠癌患者50例,将其随机分为观察组和对照组,每组25例.观察组患者在术前进行西妥昔单抗和FOLFIRI方案的联合化疗后再行腹腔镜手术治疗,而对照组患者于术前进行FOLFIRI方案化疗后再行腹腔镜手术治疗,比较两组患者的临床疗效及药物的毒副反应情况.结果 观察组患者的生存质量改善率为80.0%,显著高于对照组48.0%,且两者之间的差异有统计学意义（χ2=5.638,P〈0.05）.结论 术前西妥昔单抗和FOLFIRI方案化疗联合腹腔镜手术治疗晚期转移性结直肠癌的疗效显著,毒副反应较少且轻微,患者耐受性好.

Clinical Efficacy of Cetuximab Plus FOLFIRI Regimen as Pre-operative Treatment Combined with Iaparoscopic Surgery for Patients with Advanced Metastatic Colorectal Cancer

Objective To observe the clinical efficacy of cetuximab plus FOLFIRI regimen as pre-operative treatment in combination with laparoscopic surgery for patients with advanced metastatic colorectal cancer. Methods Fifty patients with advanced metastatic colorectal cancer were divided into observation group and control group（25 cases each） randomly. The observation group received pre operative treatment with cetuximab plus FOLFIRI regimen chemotherapy in combination with laparoscopic surgery, and control group received laparoscopic surgery only. The clinical efficacy and side-effect of the two groups were measured and compared. Results The improvement rate of quality life was obviously higher in the observation group than that in the control group（80.0 % vs 48.00% ） and there was a statistical significance（x2 = 5. 638,P〈0.05）. Conclusion Cetuximab plus FOLFIRI regimen as pre-operative treatment in combination with laparoscopic surgery for patients with advanced metastatic colorectal cancer has remarkable curative effect, with a few side effects and favorable tolerance.